Berotralstat should not be used for treatment of acute attacks of hereditary angioedema. Additional doses or doses of berotralstat higher than 150 mg once daily are not recommended. An increase in QT was observed at dosages higher than the recommended 150 mg once daily dosage and was concentration dependent.
- TRADE NAME: Orladeyo (BioCryst)
- INDICATIONS:
A prophylactic for the prevention of attacks of hereditary angioedema.
- CLASS: Kallikrein inhibitor
- HALF-LIFE: ~ 93 hours
- FDA APPROVAL DATE: 12/03/2020
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Cyclosporine, P-gp inhibitors, P-gp inducers, BCRP inhibitors, Rifampin, St John's Wort - PREGNANCY: Insufficient data in pregnant women available to inform drug-related risks with use in pregnancy.
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
